Oxidative polymorphism of debrisoquine is not related to human colo-rectal cancer
✍ Scribed by J. M. Ladero; J. Benítez; J. F. González; E. Vargas; M. Díaz-Rubio
- Publisher
- Springer
- Year
- 1991
- Tongue
- English
- Weight
- 343 KB
- Volume
- 40
- Category
- Article
- ISSN
- 0031-6970
No coin nor oath required. For personal study only.
✦ Synopsis
The oxidative polymorphism of debrisoquine (DBQ) has been determined in 89 patients with colo-rectal cancer and in 556 normal control subjects. Four patients and 34 controls, with a metabolic ratio greater than 12.6, were classified as poor metabolisers of DBQ (n.s.). No difference was found in the distribution of the frequencies of the MR of DBQ between patients and controls. It is concluded that polymorphic oxidation of DBQ is not related to the risk of developing colo-rectal cancer in human beings.
📜 SIMILAR VOLUMES
Background: Several studies have recently demonstrated that apoptosis of cancer cells is triggered by diverse adjuvant cancer therapies and the induction of apoptosis correlates with the sensitivity of the primary tumor to such therapies. Methods: We investigated the factors modulating adjuvant can
Although several oncogenes, including c-myc, ras and c-raf-I, have been implicated in cellular resistance to ionising radiation, there is less information relating oncogene expression to cisdiamminedochloroplatinum (CDDP) resistance. However, transfection of c-myc or v-H-ras and activation of protei